您的位置: 首页 > 农业专利 > 详情页

Methods for the treatment of HCV
专利权人:
ABBVIE INC.
发明人:
BARRY M. BERNSTEIN,RAJEEV M. MENON,KHATRI AMIT,MENSING SVEN,DUTTA SANDEEP,DANIEL E. COHEN,THOMAS J. PODSADECK,SCOTT C. BRUN,WALID M. AWNI,EMILY O. DUMAS,CHERI E. KLEIN
申请号:
UY34401
公开号:
UY34401A
申请日:
2012.10.19
申请国别(地区):
UY
年份:
2013
代理人:
摘要:
Therapies without interferon and Ribavirin for the treatment of HCV. Preferably, the treatment is of a shorter duration, as no more than 12 Weeks. In One aspect, the Therapies include Managing at least two Direct acting antiviral agents without interferon and Ribavirin without a Guy With a hcv infection.For example, Therapies include administering to a subject a Therapeutic effective amount of a Therapeutic Agent (1, 2 or 3 a Therapeutic Agent and a cytochrome P450 inhibitor (EG, ritonavir).Claim 2: the method of claim 1, wherein said at least two DAAS comprising: a compound 1 or a pharmaceutically acceptable Salt thereof, and a compound 4 or a pharmaceutically acceptable Salt thereof, wherein the compound 1 or the Salt thereof is co admin Istra with ritonavir.Claim 10: the method of claim 1, wherein said at least two DAAS include PSI bags-7977 and TMC - 435. Claim 14: Method of claim 1, wherein said at least two DAAS include PSI bags-7977 and daclatasvir. Claim 18: the method of claim 1, wherein said at least two DAAS include PSI bags-7977 and gs-5885.Claim 22: the method of claim 1, wherein said at least two - and 790052 DAAS include BMS BMS - 650032, and such treatment lasts for 10, 11 or 12 Weeks. Claim 28: the method of claim 1, wherein said at least two include DAAS and daclatasvir INX - 189.Terapias sin interferón y sin ribavirina para el tratamiento de HCV. Preferiblemente, el tratamiento es de una duración más breve, tal como no más de 12 semanas. En un aspecto, las terapias comprenden administrar al menos dos agentes antivirales de acción directa sin interferón y sin ribavirina a un sujeto con una infección por HCV. Por ejemplo, las terapias comprenden administrar a un sujeto cantidades eficaces de un agente terapéutico 1, un agente terapéutico 2 (o un agente terapéutico 3) y un inhibidor de la citocromo P450 (por ejemplo, ritonavir).
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充